Welcome to our dedicated page for Dynavax Technolo SEC filings (Ticker: DVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dynavax Technologies Corporation (DVAX) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as a Nasdaq Global Select Market issuer. Dynavax uses these filings to report financial results, clinical milestones and significant corporate events related to its vaccines business, including HEPLISAV-B®, CpG 1018® adjuvant and its pipeline of adjuvanted vaccine candidates.
Among the most frequently referenced documents are Form 8-K current reports. Dynavax files 8-Ks to furnish quarterly financial results, such as the second and third quarter 2025 earnings releases, under Item 2.02 (Results of Operations and Financial Condition). These filings typically attach press releases that detail HEPLISAV-B net product revenue, total revenues, research and development spending, selling, general and administrative expenses, and adjusted EBITDA, along with management commentary and updated guidance.
Dynavax also uses Form 8-K to disclose clinical and pipeline developments and corporate governance changes. For example, an August 21, 2025 8-K furnished a press release and corporate presentation on topline Phase 1/2 results for Z-1018, the company’s shingles vaccine candidate. Another 8-K dated October 15, 2025 described changes in senior management roles, including transitions in the positions of President, Chief Operating Officer and Chief Medical Officer.
In addition, Dynavax’s filings include information on its capital markets activities, such as share repurchase programs and other financial measures, and will incorporate documents related to significant transactions. The announced agreement for Sanofi to acquire Dynavax through a cash tender offer and subsequent merger is expected to generate tender offer materials on Schedule TO and a Solicitation/Recommendation Statement on Schedule 14D-9, as described in the companies’ joint press release.
On Stock Titan, users can review Dynavax’s SEC filings as they are made available from EDGAR and access AI-powered summaries that explain the key points of lengthy documents like earnings releases and transaction-related filings. This includes highlighting items such as quarterly performance trends, updates on vaccine programs like HEPLISAV-B and Z-1018, and the implications of corporate events. The page also surfaces filings related to executive changes and other material events so that investors can quickly understand what Dynavax has reported to regulators.
Dynavax Technologies director Elaine D. Sun reported the cash-out of her equity awards in connection with the company’s acquisition by Sanofi. Sanofi’s subsidiary completed a tender offer for all Dynavax common shares at $15.50 per share in cash and then merged into Dynavax on February 10, 2026.
At the merger’s effective time, all of Sun’s restricted stock units were cancelled and converted into the right to receive cash equal to the number of underlying shares multiplied by the $15.50 offer price. Multiple stock option awards were also fully vested, then cancelled and converted into cash equal to the number of option shares multiplied by the excess of the $15.50 offer price over each option’s exercise price. Following these transactions, the Form 4 shows zero RSUs and options beneficially owned.
The Form 4 shows that Dynavax Technologies director Daniel L. Kisner had his equity cashed out in connection with the company’s merger with Sanofi. On February 10, 2026, Sanofi’s subsidiary completed a tender offer and merger, paying $15.50 per share for Dynavax common stock.
At the merger’s effective time, each share of common stock held by Kisner, including 1,500 common shares, was exchanged for cash at $15.50 per share. All of his restricted stock units covering 21,829 shares were cancelled and converted into cash based on the same price.
Multiple stock options with various exercise prices were first fully vested, then cancelled and converted into cash equal to the number of option shares multiplied by the difference between the $15.50 offer price and each option’s exercise price. Following these transactions, Kisner reported zero shares and zero options beneficially owned.
Dynavax Technologies director Brent MacGregor reported the cash-out of his equity awards tied to Sanofi’s acquisition of the company. Sanofi’s subsidiary completed a tender offer to buy all Dynavax common shares for $15.50 per share in cash and then merged into Dynavax on February 10, 2026, leaving Dynavax as an indirect wholly owned subsidiary.
At the merger’s effective time, MacGregor’s 21,829 restricted stock units were cancelled and converted into the right to receive cash equal to the underlying shares multiplied by the $15.50 offer price. Multiple stock option grants with exercise prices between $8.20 and $11.85, covering blocks of 50,000, 25,000, 22,500 and 28,500 Dynavax shares, became fully vested and were then cancelled in exchange for cash equal to the number of option shares times the excess of the offer price over each option’s exercise price.
Following these transactions, the Form 4 shows MacGregor with zero Dynavax shares and options beneficially owned directly.
Dynavax Technologies director Lauren Silvernail reported the cash-out of her equity awards in connection with the company’s acquisition by Sanofi. Sanofi’s subsidiary completed a tender offer for all Dynavax common shares at $15.50 per share in cash and then merged into Dynavax on February 10, 2026, leaving Dynavax as an indirect wholly owned subsidiary.
At the merger’s effective time, 10,075 restricted stock units held by Silvernail were cancelled and converted into the right to receive cash equal to the shares underlying the RSUs multiplied by the $15.50 offer price. Two stock option grants covering 42,750 and 7,125 Dynavax shares first became fully vested, then were cancelled and converted into cash based on the number of underlying shares and the excess of the $15.50 offer price over each option’s exercise price. Following these transactions, the Form 4 shows 0 units and 0 options remaining beneficially owned.
Dynavax Technologies director Francis Cano reported automatic changes to his equity on February 10, 2026, tied to the company’s merger with SANOFI. SANOFI’s subsidiary completed a tender offer to acquire all Dynavax common shares for $15.50 per share in cash, then merged into Dynavax, which became an indirect wholly owned subsidiary.
At the merger’s effective time, all restricted stock units held by Cano were cancelled and converted into a cash right equal to the shares underlying each award multiplied by the $15.50 offer price. His stock options first became fully vested, then were cancelled and converted into cash equal to the number of option shares multiplied by the excess of the $15.50 offer price over each option’s exercise price.
Dynavax Technologies President & COO David F. Novack reported automatic changes to his equity awards tied to the acquisition of Dynavax by Sanofi. Under a Merger Agreement, Sanofi’s subsidiary completed a tender offer for all Dynavax common shares at $15.50 per share in cash, then merged into Dynavax on February 10, 2026, leaving Dynavax as an indirect wholly owned subsidiary.
At the merger’s effective time, each Dynavax share held by Novack was exchanged for the $15.50 offer price. All outstanding stock options, performance stock units (PSUs) and restricted stock units (RSUs) were cancelled and converted into cash based on the offer price and the number of underlying shares. For equity awards granted in 2025, half of the related cash amount remains subject to vesting and is scheduled to vest six months after the effective time.
Dynavax Technologies Corp. filed a Form 25 indicating that its common stock is being removed from listing and/or registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq certifies that it has complied with its own rules and relevant SEC regulations to strike this class of securities from listing or withdraw its registration.
Dynavax Technologies Corporation has completed its acquisition by Sanofi through a tender offer and follow‑on merger, cashing out each share of common stock for $15.50 in cash, without interest and subject to taxes. The tender offer expired on February 9, 2026, with 84,680,752 shares validly tendered, representing about 73.92% of outstanding shares, satisfying the minimum condition for closing.
Following the merger under Delaware law, Dynavax became an indirect wholly owned subsidiary of Sanofi, and the company requested that Nasdaq halt trading, delist the shares and file to deregister them. Convertible notes due 2026 and 2030 were amended so conversions now deliver cash based on the existing conversion rate multiplied by $15.50. Equity awards were largely cashed out at the merger price, with a portion of recent unvested grants converted into cash‑based awards that vest six months after closing, generally accelerating on involuntary termination.
The entire pre‑merger board resigned at closing and was replaced by Sanofi‑designated directors and officers. Certain senior executives received excise tax reimbursement protections on merger‑related payments, subject to individual caps.
Dynavax Technologies reports the final results of Sanofi’s tender offer to acquire the company. The offer expired on February 9, 2026, with 84,680,752 shares validly tendered, representing about 73.92% of outstanding shares, satisfying the minimum condition.
Sanofi’s acquisition vehicle has accepted these shares for payment at $15.50 per share in cash. Using Delaware’s Section 251(h), Sanofi plans to complete a short-form merger without a stockholder meeting, after which remaining Dynavax shares will be converted into the same cash consideration, the stock will be delisted from Nasdaq, and registration under the Exchange Act will be terminated.